Drug intelligence / Profile preview

SinaCurcumin

Development stage: Phase 2
Lead developer: Exir Nano Sina
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral, Topical

Overview

SinaCurcumin is a proprietary oral nano-micellar formulation of curcumin (the primary active polyphenolic compound found in turmeric) developed by Exir Nano Sina. The formulation utilizes nanotechnology to encapsulate curcuminoids within nanomicelles, which significantly overcomes the inherent limitations of curcumin, such as poor water solubility and low systemic bioavailability. SinaCurcumin exerts a range of anti-inflammatory, antioxidant, and immunomodulatory effects. Mechanistically, it has been shown to suppress the expression of cyclin D1, downregulate pro-inflammatory cytokines, and enhance the population of regulatory T (Treg) cells by upregulating FoxP3 and anti-inflammatory cytokines like IL-10 and TGF-beta. It has been evaluated in numerous clinical trials for its therapeutic potential in conditions including COVID-19, ulcerative colitis, osteoarthritis, and radiation-induced oral mucositis.

Brand names: SinaCurcumin
Other names: nano-curcuminnanomicellar curcuminSinaCurcumin-40SinaCurcumin40SinaCurcumin 40SinaCurcumin-80SinaCurcumin80SinaCurcumin 80

Targets

FOXP3 (Forkhead box protein P3)IL10 (Interleukin-10)TGFB (GARP–latent transforming growth factor beta 1 complex)CCND1 (Cyclin D1)IL-35 (Interleukin-35)

Beyond the preview

Go deeper on SinaCurcumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SinaCurcumin.

Explore the full profile